An Open Trial of Clozapine in Thirty-Six Adolescents with Schizophrenia

Journal of Child and Adolescent Psychopharmacology

Volumn 4, Issue 1, 1994, Pages 31-41

  Remschmidt, Helmut ^a   Schulz, Eberhard ^a   Martin, P d Matthias ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; FLUPHENAZINE; HALOPERIDOL;

ADOLESCENT; AGRANULOCYTOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERANCE; ELECTROENCEPHALOGRAM; FEMALE; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PSYCHOSIS; SCHIZOPHRENIA; STUPOR;

EID: 0028223382     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.1994.4.31     Document Type: Article

References (35)

1. Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA: Clozapine-induced agranulocytosis. N Engl J Med 329: 162–167, 1993
2. American Psychiatric Association (APA): Diagnostic and Statistical Manual of Mental Disorders, 3rd ed. rev. (DSM-III-R). Washington, DC, APA, 1987.
3. Andreasen NC, Olsen S: Negative vs. positive schizophrenia. Definition and validation. Arch Gen Psychiatry 39: 789–794, 1982
4. Andreasen NC: Scale for the Assessment of Negative Symptoms (SANS), Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, Iowa, University of Iowa, 1984
5. Andreasen NC, Flaum M, Swayze V, Tyrrell G, Arndt S: Positive and negative symptoms in schizophrenia. A critical reappraisal. Arch Gen Psychiatry 47: 615–621, 1990
6. Angst J, Jaenicke U, Padrutt A, Scharfetter C.H.: Ergebnisse eines Doppelblindversuches von HF 1854 (8-Chlor-ll(4-Methyl-l-Piperazenyl)-5H-Dibenzo[be](l,4)Diazepin) im Vergleich zu Levomepromazin. Pharmakopsychiatrie 4: 192–200, 1971a
7. Angst J, Bente D, Berner P: Das klinische Wirkungsbild von Clozapin (Untersuchung mit dem AMP-System). Pharmakopsychiatrie 4: 200–211, 1971b
8. Birmaher B, Baker R, Kapur S, Quintana H, Ganguli R: Case study: Clozapine for the treatment of adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 31: 160–164, 1992
9. Braun-Scharm H, Martinius J: EEG-Veranderungen und Anfalle unter Clozapinmedikation bei schizophrenen Jugendlichen. Z Kinder Jugenpsychiatr 19: 164–169, 1991
10. Bunney BS: Clozapine: A hypothesized mechanism for its unique clinical profile. Br J Psychiatry 160(Suppl 17): 17–21, 1992
11. Coward DM: General pharmacology of clozapine. Br J Psychiatry 160(Suppl 17):5–11, 1992
12. Farde L, Nordstrom AL: PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br J Psychiatry 160(Suppl 17):30–33, 1992
13. Gerlach J, Hansen L: Clozapine and D1/D2 antagonism in extrapyramidal functions. Br J Psychiatry 160(Suppl 17):34–37, 1992
14. Gunther W, Baghai T, Naber D, Spatz R, Kugler J: EEG-Veranderungen und Krampfanfalle wahrend der Behandlumg mit Clozapin (Leponex). In: Clozapin. Pharmakologie und Klinik eines atypischen Neuroleptikums—eine kritische Bestandsaufnahme. Edited by Naber D, Muller-Spahn F. Stuttgart-New York, Schattauer, 1992, pp 135–146
15. Kane JM: Clinical efficacy of clozapine in treatment-refractory schizophrenia: An overview. Br J Psychiatry 160(Suppl 17):41–45, 1992
16. Kane JM, Honigfeld G, Singer J, Meltzer H: Clozapine in treatment resistant schizophrenics. Psychopharmacol Bull 24: 62–67, 1988
17. Klimke A, Klieser E: Clozapin—geschichtliche Entwicklung und aktuelle Fragen. In: Clozapin. Pharmakologie und Klinik eines atypischen Neuroleptikums—eine kritische Bestandsaufnahme. Edited by Naber D, Muller-Spahn F. Stuttgart-New York, Schattauer, 1992, pp 3–10
18. Kurtz G, Kapfhammer H-P, Peuker B: Pisa-Syndrom unter Clozapintherapie. Nervenarzt 64: 742–746, 1993
19. Lieberman J, Johns C, Cooper T, Pollack S, Kane J: Clozapine pharmacology and tardive dyskinesia. Psychopharmacol 99: 54–59, 1989
20. Lieberman JA, Kane JM, Johns CA: Clozapine—guidelines for clinical management. J Clin Psychiatry 50: 329–338, 1990
21. Lindstrom LH: The effect of long-term treatment with clozapine in schizophrenia: A retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand 77: 524–529, 1988
22. Meltzer HY: The effect of clozapine and other atypical antipsychotic drugs on negative symptoms. In: Negative versus Positive Schizophrenia. Edited by Marneros A, Andreasen NC, Tsuang MT. Berlin-Heidelberg-New York, Springer-Verlag, 1991, pp 365–376
23. Meltzer HY: The importance of serotonin-dopamine interactions in the action of clozapine. Br J Psychiatry 160(Suppl 17):22–29, 1992
24. Naber D, Hippius H: The European experience with the use of clozapine. Hosp Community Psychiatry 41: 886–890, 1990
25. Naber D, Muller-Spahn F (eds): Clozapin. Pharmakologie und Klinik eines atypischen Neuroleptikums—eine kritische Bestandsaufnahme. Stuttgart-New York, Schattauer, 1992
26. Remschmidt H, Martin M: Die Therapie der Schizophrenie im Jugendalter. Deutsches Arzteblatt 89: 387–396, 1992
27. Remschmidt H, Martin M, Schulz E, Gutenbrunner C, Fleischhaker C: The concept of positive and negative schizophrenia in child and adolescent psychiatry. In: Negative versus Positive Schizophrenia. Edited by Marneros A, Andreasen NC, Tsuang MT. Berlin-Heidelberg-New York, Springer-Verlag, 1991, pp 219–242
28. Remschmidt H, Schulz E, Martin M: Die Behandlung schizophrener Psychosen in der Adoleszenz mit Clozapin (Leponex). In: Clozapin. Pharmakologie und Klinik eines atypischen Neuroleptikums—eine kritische Bestandsaufnahme. Edited by Naber D, Muller-Spahn F. Stuttgart-New York, Schattauer, 1992, pp 99–119
29. Rutter M, Shaffer D, Sturge C: A guide to a multi-axial classification scheme for psychiatric disorders in childhood and adolescence. London, Institute of Psychiatry, 1976
30. Safferman AZ, Lieberman JA, Pollack S, Kane JM: Akathisia and clozapine treatment. J Clin Psychopharmacol 13: 286–287, 1993
31. Schmidt LG: Unerwunschte Wirkungen von Clozapin (Leponex): Ergebnisse der AMUP-Studie 1979-1988. In: Clozapin. Pharmakologie und Klinik eines atypischen Neuroleptikums—eine kritische Bestandsaufnahme. Edited by Naber D, Muller-Spahn F. Stuttgart-New York, Schattauer, 1992, pp 127–134
32. Schmidt MH, Trott GE, Blanz B, Nissen G: Clozapine medication in adolescents. In: Psychiatry: A World Perspective, Vol. I (Proceedings of the VIII World Congress of Psychiatry, Athens, 12-19 October 1989). Edited by Stefanis CN, Rabavilas AD, Soldates CR. Amsterdam-New York-Oxford, Excerpta Medica, 1990, pp 1100–1104
33. Siefen RG, Remschmidt H: Behandlung mit Clozapin bei schizophrenen Jugendlichen. Z Kinder Jugenpsychiatr 14: 245–257, 1986
34. Stille G, Hippius H: Kritische Stellungnahme zum Begriff der Neuroleptika (und von pharmakologischen und klinischen Befunden mit Clozapin). ). Pharmakopsychiatrie 4: 182–191, 1971
35. World Health Organization: Tenth Revision of the International Classification of Diseases (ICD-10), Chapter V (F): Mental and Behavioural Disorders (including Disorders of Psychological Development). Clinical Descriptions and Diagnostic Guidelines. Geneva, World Health Organization, 1991